Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Capital Product Partners L.P. (CPLP) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Capital Product Partners L.P. (CPLP) - free report >>
Image: Bigstock
Top Ranked Value Stocks to Buy for December 7th
Here are three stocks with buy rank and strong value characteristics for investors to consider today, December 7th:
Innoviva, Inc. (INVA - Free Report) : This pharmaceuticals company has a Zacks Rank #1 (Strong Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 24.3% over the last 60 days.
Innoviva, Inc. Price and Consensus
Innoviva, Inc. price-consensus-chart | Innoviva, Inc. Quote
Innoviva has a price-to-earnings ratio (P/E) of 4.78, compared with 14.80 for the industry. The company possesses a Value Score of A.
Innoviva, Inc. PE Ratio (TTM)
Innoviva, Inc. pe-ratio-ttm | Innoviva, Inc. Quote
Capital Product Partners L.P. (CPLP - Free Report) : This shipping company that provides marine transportation services has a Zacks Rank #2 (Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 9.6% over the last 60 days.
Capital Product Partners L.P. Price and Consensus
Capital Product Partners L.P. price-consensus-chart | Capital Product Partners L.P. Quote
Capital Product Partners has a price-to-earnings ratio (P/E) of 4.67, compared with 9.40 for the industry. The company possesses a Value Score of A.
Capital Product Partners L.P. PE Ratio (TTM)
Capital Product Partners L.P. pe-ratio-ttm | Capital Product Partners L.P. Quote
360 DigiTech, Inc. (QFIN - Free Report) : This data driven, technology empowered digital platform has a Zacks Rank #2, and seen the Zacks Consensus Estimate for its current year earnings rising 19% over the last 60 days.
360 DigiTech, Inc. Price and Consensus
360 DigiTech, Inc. price-consensus-chart | 360 DigiTech, Inc. Quote
360 DigiTech has a price-to-earnings ratio (P/E) of 3.56, compared with 30.00 for the industry. The company possesses a Value Score of A.
360 DigiTech, Inc. PE Ratio (TTM)
360 DigiTech, Inc. pe-ratio-ttm | 360 DigiTech, Inc. Quote
See the full list of top ranked stocks here.
Learn more about the Value score and how it is calculated here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>